Characteristics and evolution of fractures of hip operated in the Prosthetics Bank (January-December 2013)
Abstract
Introduction: hip fracture due to frailty is considered a marker of osteoporotic disease in the elderly population. It determines a high morbidity and mortality and high health costs. Objectives: to analyze characteristics and evolution after a hip fracture due to fragility in patients over 65 years of age assisted in the Banco de Protesis during the January-June 2013 period.
Methods: historical cohort follow-up study, consisting of 184 patients. The data was obtained from the medical records and the follow-up was done by telephone. The maximum follow-up time was 84 weeks.
Results: 82% of patients were female, with median age of 80.7 years for men and 82.7 for women. The most frequent comorbidities were hypertension and cardiovascular disease. There were no differences in the right or left location, the majority corresponded to femoral neck fractures. The median resolution time was 9 days for arthroplasty and 11 days for osteosynthesis. The fall was the determinant in 94.5% of the cases. Twenty-six percent of the patients had previous fragility fractures. 85% of individuals did not know about osteoporosis (OP) and 69% did not receive treatment for this disease. 9% was institutionalized, 77% managed to resume walking. 15% died in the follow-up period.
Conclusions: osteoporosis is not recognized or treated in patients with fragility fracture hi
References
(1) Uruguay. Fondo Nacional de Recursos. Informe anual de autorizaciones 2013. Disponible en: http://www.fnr.gub.uy/ sites/default/files/estadisticas/ia2013/ia_aut_2013_1.pdf (Consulta: 16 febrero 2018).
(2) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis and therapy. JAMA 2001; 285(6):785-95.
(3) Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 2003; 51:364-70.
(4) Alarcón Alarcón T, González-Montalvo JI. Fractura osteoporótica de cadera. Factores predictivos de recuperación funcional a corto y largo plazo. An Med Interna (Madrid) 2004; 21:49-58.
(5) Port L, Center J, Briffa NK, Nguyen T, Cumming R, Eisman J. Osteoporotic fracture: missed opportunity for intervention. Osteoporosis Int 2003; 14:780-4.
(6) Lee YK, Ha YC, Yoon BH, Koo KH. Incidence of second hip fracture and compliant use of bisphosphonate. Osteoporos Int 2013; 24:2099-104.
(7) RabendaV, Vanoverloop J, Fabri V, Mertens R, Sumkay F, Vannecke C, et al. Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am 2008; 90:2142-8.
(8) Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 2004; 15(10):767-78.
(9) Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357(18):1799-809.
(10) Osaki M, Tatsuki K, Hashikawa T, Norimatsu T, Chiba K, Motokawa S, et al. Beneficial effect of risedronato for preventing recurrent hip fracture in the elderly Japanese women. Osteoporos Int 2012; 23:695-703.
(11) Melton LJ 3rd. Epidemiology worldwide. Endocrinol Metab Clin North Am 2003; 32:1-13.
(12) Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17:1726-33.
(13) Lofman O, Berglund K, Larsson L, Toss G. Changes in hip fracture epidemiology: redistribution between ages, genders and fracture types. Osteoporos Int 2002; 13:18-25.
(14) Follin SL, Black JN, McDermott MT. Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy 2003; 23:190-8.
(15) Fukui N, Watanabe Y, Nakano T, Sawaguchi T, Matsuchita T. Predictors for ambulatory ability and the change in ADL after hip fracture in patient with different levels of mobility before injury: a 1-yer prospective cohort study. J Orthop Trauma 2012; 26:163-71.
(16) Sennerby U, Melhus H, Gedeborg R, Byberg L, Garmo H, Ahlbom A, et al. Cardiovascular diseases and risk of hip fracture. JAMA 2009; 302(15):1666-73.
(17) Xu B, Han L, Liu H, Wang J, Bao XY, Xi HX, et al. Cardiovascular disease and hip fracture among older inpatients in Beijing, China. Biomed Res Int 2013; 2013. doi:10.1155/ 2013/493696.
(18) Sprini D, Rini GB, Di Stefano L, Cianferotti L, Napoli N. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab 2014; 11(2):117-9.
(19) Albornoz H, Gambogi R, Debenedetti A, Gonzalez MC, Scarpitta C. Seguimiento prospectivo de artroplastia de cadera por fractura (2002). En: Fondo Nacional de Recursos. La artroplastia de cadera y rodilla. Montevideo: FNR, 2009:39-92. (Publicación técnica, 9). Disponible en: www.fnr.gub.uy/sites/default/files/publicaciones/FNR_publicacion_tecnica_9.pdf (Consulta: 24 setiembre 2018).
(20) Simunovic N, Devereaux PJ, Sprague S, Guyatt GH, Schemitsch E, Debeer J, et al. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ 2010; 182:1609-16.
(21) Norton R, Campbell A, Lee-Joe T, Robinson E, Butler M. Circumstances of falls resulting in hip fractures among older people. J Am Geriatr Soc 1997; 45(9):1108-12.
(22) Allander E, Gullberg B, Johnell O, Kanis J, Ranstam J, Elffors L. Circumstances around the fall in a multinational hip fracture risk study: a diverse pattern for prevention. Accid Anal Prev 1998; 30(5):607-16.
(23) Giangregorio L, Papaioannou A, Thabane L, DeBeer J, Cranney A, Dolovich L, et al. Do patients perceive a link between a fragility fracture and osteoporosis? BMC Musculoskelet Disord 2008; 9:38.
(24) Chevalley T, Hoffmeyer P, Bonjour JP, Rizzoli R. An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int 2002; 13:450-5.
(25) Harrington JT, Broy SB, Derosa AM, Licata AA, Shewmon DA. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum 2002; 47:651-4.
(26) Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporosis Int 2004; 15:767-78.
(27) Lems WF, Dreinhofer KE, Bischoff-Ferrari H, Blauth M, Czerwinski E, da Silva J, et al. EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. Ann Rheum 2017; 76(5):802-10.
(28) Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 2010; 58(4):650-7.
(29) Khosla S, Shane E. A crisis in the treatment of osteoporosis. J Bone Miner Res 2016; 31:1485-7.
(30) León Vázquez F, Bonis J, Bryant Cerezo V, Herrero Hernández S, Jamart Sánchez L, Díaz Holgado A. Prevención de fractura osteoporótica en España: uso de fármacos antes y después de una fractura de cadera. Rev Osteoporos Metab Miner 2015; 7(2):54-62.
(31) Zhu Y, Chen W, Sun T, Zhang Q, Cheng J, Zhang Y. Meta-analysis of risk factors for the second hip fracture (SHF) in elderly patients. Arch Gerontol Geriatr 2014; 59(1):1-6.
(32) Scaglione M, Fabbri L, Di Rollo F, Bianchi MG, Dell’omo D, Guido G. The second hip fracture in osteoporotic patients: not only an orthopaedic matter. Clin Cases Miner Bone Metab 2013; 10(2):124-8.
(33) Cumming RG, Klineberg R, Katelaris A. Cohort study of risk of institutionalisation after hip fracture. Aust N Z Public Health 1996; 20(6):579-82.
(34) Alarcón Alarcón T, González-Montalvo JI. Fractura osteoporótica de cadera. Factores predictivos de recuperación funcional a corto y largo plazo. An Med Interna (Madrid) 2004; 21:49-58.
(35) Farahmand BY, Michae Isson K, Ahlbom A, Ljunghall S, Baron JA. Survival after hip fracture. Osteoporos Int 2005; 16:1583-90.
(36) Richmond J, Aharonoff GB, Zuckerman JD, Koval KJ. Mortality risk after hip fracture. J Orthop Trauma 2003; 17(1):53-6.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
